≡ Risteys
R10

Documentation Changelog GitHub Contact & Feedback

Hyperparathyroidism

DOID EFO MESH SNOMED Endpoint Browser PheWeb

E4_HYPERPARA

hyperparathyroidism: Hyperfunction of the parathyroid glands resulting in the overproduction of parathyroid hormone. It may be primary or secondary; primary hyperparathyroidism is caused by parathyroid adenoma, parathyroid hyperplasia, parathyroid carcinoma, and multiple endocrine neoplasia. It is associated with hypercalcemia and hypophosphatemia. Signs and symptoms include weakness, fatigue, nausea, vomiting, constipation, depression, bone pain, osteoporosis, cystic bone lesions, and kidney stones. Secondary hyperparathyroidism is caused by the chronic stimulation of the parathyroid glands in patients with chronic renal failure, rickets, and malabsorption syndromes.

Endpoint definition

↥
FinnGen phenotype data

429209 individuals

diagram downward connector

Apply sex-specific rule None

429209

diagram downward connector

Check conditions None

429209

diagram downward connector
diagram bullet

Check pre-conditions, main-only, mode, registry filters

Hospital Discharge: ICD-10 E21.09, E21.1, E21.2, E21.3
Hospital discharge: ICD-9 2520
Hospital discharge: ICD-8 2520
Cause of death: ICD-10 E21.09, E21.1, E21.2, E21.3
Cause of death: ICD-9 2520
Cause of death: ICD-8 2520
Medicine purchases: ATC H05B

3 out of 7 registries used, show all original rules.

6299

diagram downward connector
diagram bullet

Check minimum number of events

Min. number of events 3

6299

diagram downward connector

Include endpoints None

6299

diagram downward connector
diagram bullet diagram downward connector

Remove individuals based on genotype QC

6094

diagram downward connector
E4_HYPERPARA

Control definitions

Control exclude E4_ENDOGLAND

Extra metadata

Level in the ICD hierarchy 4
First used in FinnGen datafreeze DF2

Summary Statistics

↥

Key figures

All Female Male
Number of individuals 6094 4430 1664
Unadjusted prevalence (%) 1.48 1.92 0.92
Mean age at first event (years) 63.38 63.10 64.13

Mortality

Follow-up Absolute risk HR [95% CI] p N
1998–2019 0.06 2.91 [2.36, 3.59] 1.1e-23 1500
15 years 0.01 1.82 [1.56, 2.12] 4.6e-14 713
5 years 0.00 2.92 [2.56, 3.34] 2.1e-56 442
1 year 0.00 4.25 [3.47, 5.20] 3.2e-44 129

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

↥

Index endpoint: E4_HYPERPARA – Hyperparathyroidism
GWS hits: 9

Survival analyses between endpoints

↥

Plot

before Hyperparathyroidism
after Hyperparathyroidism

loading spinner Loading survival analyses plot

Drugs most likely to be purchased after Hyperparathyroidism

↥

Endpoint not on priority list, no data to show.